Technical Analysis for GTHX - G1 Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 12.76 -0.31% -0.04
GTHX closed down 0.31 percent on Friday, October 23, 2020, on 22 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical GTHX trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Crossed Above 20 DMA Bullish -0.31%
20 DMA Resistance Bearish 2.57%
Doji - Bullish? Reversal 2.57%
Down 3 Days in a Row Weakness 2.57%
Fell Below 20 DMA Bearish 1.67%
Overbought Stochastic Strength 1.67%
Bearish Engulfing Bearish -2.82%
Stochastic Sell Signal Bearish -2.82%
Weak + Overbought Other -2.82%
Older End-of-Day Gignals for GTHX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
20 DMA Support 2 days ago
Down 2 % 2 days ago
Rose Above Previous Day's High 2 days ago
Down 1% 2 days ago
Up 1% 2 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
Biopharmaceutical Cancer Drugs Treatment Of Cancer Breast Cancer Hormones Astrazeneca Protein Kinase Inhibitors Her2/Neu Treatment Of Breast Cancer Antiestrogens Selective Estrogen Receptor Degraders

Is GTHX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 31.34
52 Week Low 8.8
Average Volume 714,283
200-Day Moving Average 16.59
50-Day Moving Average 14.20
20-Day Moving Average 12.64
10-Day Moving Average 13.02
Average True Range 0.71
ADX 15.7
+DI 18.75
-DI 23.16
Chandelier Exit (Long, 3 ATRs ) 11.74
Chandelier Exit (Short, 3 ATRs ) 13.46
Upper Bollinger Band 13.80
Lower Bollinger Band 11.48
Percent B (%b) 0.55
BandWidth 18.30
MACD Line -0.36
MACD Signal Line -0.46
MACD Histogram 0.1053
Fundamentals Value
Market Cap 485.07 Million
Num Shares 38 Million
EPS -2.70
Price-to-Earnings (P/E) Ratio -4.72
Price-to-Sales 238.53
Price-to-Book 2.53
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.48
Resistance 3 (R3) 13.47 13.23 13.36
Resistance 2 (R2) 13.23 13.04 13.23 13.32
Resistance 1 (R1) 12.99 12.93 12.87 13.00 13.28
Pivot Point 12.75 12.75 12.69 12.75 12.75
Support 1 (S1) 12.51 12.56 12.39 12.52 12.24
Support 2 (S2) 12.27 12.45 12.27 12.20
Support 3 (S3) 12.03 12.27 12.16
Support 4 (S4) 12.04